The unbearable versatility of endocrine aging

Ageing is multifactorial, genetically and epigenetically programmed biological process. Nowadays ageing is acknowledged as extremely actual scientifical, social and demographical problem. Despite the evidence of interactions between ageing and accumulation of endocrine disruptions, the last 150 years of variegated searches for potential endocrine “elixir of lon gevity” brought contradictive, mutually exclusive and even discouraging results. Fortunately, the discovery of referent lab oratory intervals of hormonal blood levels among elderly people improved the overall situation. Traditional treatment of endocrine hormonal deficiency with replacement therapy does not lead to rejuvenation but to potential damage. That’s why it is more accepted to interpret hormonal changes among elderly people not only as aging but specific adaptation for “successful ageing”. The present review contains modern datas about endocrine ageing of thyroid gland, adrenal glands (hy percorticism, adrenopause), pituitary gland (somatopause, hypoprolactinemia), male (andropause) and female (menopause, hyperandrogenism) hypogonadism.

1. Fact sheet of WHO «Ageing and health», 1st October 2025 // https://www.who.int/ru/news-room/fact-sheets/detail/ageing-and-health?ysclid=mkwad6p9ml625390880

2. Melmed S, Auchus RJ, Goldfine AB, Kopp PA. & (Eds.). Williams textbook of endocrinology (15th ed.). Elsevier Science – pp. 1862. 2024. ISBN-10: 0323932304

3. Veldhuis JD. Aging and hormones of the hypothalamo pituitary axis: gonadotropic axis in men and somatotropic axes in men and women. Ageing Res Rev. 2008;7(3):189-208. doi: https://doi.org/10.1016/j.arr.2007.12.005

4. Ji Z, Liu GH, Qu J. Mitochondrial sirtuins, metabolism, and aging. J Genet Genomics. 2022;49(4):287-298. doi: https://doi.org/10.1016/j.jgg.2021.11.005

5. Iglesias P. Muscle in Endocrinology: From Skeletal Muscle Hormone Regulation to Myokine Secretion and Its Implications in Endocrine Metabolic Diseases. J Clin Med. 2025;14(13):4490. Published 2025 Jun 25. doi: https://doi.org/10.3390/jcm14134490

6. Laron Z, Werner H. Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome. Endocr Relat Cancer. 2023;30(9):e220394. Published 2023 Jul 28. doi: https://doi.org/10.1530/ERC-22-0394

7. Monzani F, Del Guerra P, Caraccio N, et al. Age-related modifications in the regulation of the hypothalamic-pituitary-thyroid axis. Horm Res. 1996;46(3):107-112. doi: https://doi.org/10.1159/000185005

8. Albert M, Jenike M, Nixon R, Nobel K. Thyrotropin response to thyrotropin-releasing hormone in patients with dementia of the Alzheimer type. Biol Psychiatry. 1993;33(4):267-271. doi: https://doi.org/10.1016/0006-3223(93)90293-m

9. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-499. doi: https://doi.org/10.1210/jcem.87.2.8182

10. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. doi: https://doi.org/10.1089/thy.2014.0028

11. Sherman BM, Pfohl B, Winokur G. The correspondence of plasma ACTH and cortisol before and after dexamethasone in healthy and depressed subjects. Psychiatr Med. 1985;3(1):41-52

12. Otte C, Hart S, Neylan TC, Marmar CR, Yaffe K, Mohr DC. A meta analysis of cortisol response to challenge in human aging: importance of gender. Psychoneuroendocrinology. 2005;30(1):80-91. doi: https://doi.org/10.1016/j.psyneuen.2004.06.002

13. Ennis GE, An Y, Resnick SM, Ferrucci L, O'Brien RJ, Moffat SD. Long-term cortisol measures predict Alzheimer disease risk. Neurology. 2017;88(4):371-378. doi: https://doi.org/10.1212/WNL.0000000000003537

14. Salardini A, Himali JJ, Abdullah MS, et al. Elevated serum cortisol associated with early-detected increase of brain amyloid deposition in Alzheimer's disease imaging biomarkers among menopausal women: The Framingham Heart Study. Alzheimers Dement. 2025;21(4):e70179. doi: https://doi.org/10.1002/alz.70179

15. Liu F, Yang Q, Yang K, et al. Cortisol Circadian Rhythm and Sarcopenia in Patients With Type 2 Diabetes: A Cross-Sectional Study. J Cachexia Sarcopenia Muscle. 2025;16(1):e13727. doi: https://doi.org/10.1002/jcsm.13727

16. Papadopoulou-Marketou N, Kassi E, Chrousos GP. Adrenal Androgens and Aging. In: Feingold KR, Adler RA, Ahmed SF, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; January 18, 2023

17. Baulieu EE. Androgens and aging men. Mol Cell Endocrinol. 2002;198(1-2):41-49. doi: https://doi.org/10.1016/s0303-7207(02)00367-2

18. Parker CR Jr. Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in the human adrenal during development and aging. Steroids. 1999;64(9):640-647. doi: https://doi.org/10.1016/s0039-128x(99)00046-x

19. Yen SS, Laughlin GA. Aging and the adrenal cortex. Exp Gerontol. 1998;33(7-8):897-910. doi: https://doi.org/10.1016/s0531-5565(98)00046-1

20. Lasley BL, Santoro N, Randolf JF, et al. The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity. J Clin Endocrinol Metab. 2002;87(8):3760-3767. doi: https://doi.org/10.1210/jcem.87.8.8741

21. Lasley BL, Crawford SL, Laughlin GA, et al. Circulating dehydroepiandrosterone sulfate levels in women who underwent bilateral salpingo-oophorectomy during the menopausal transition. Menopause. 2011;18(5):494-498. doi: https://doi.org/10.1097/gme.0b013e3181fb53fc

22. Lasley BL, Crawford S, McConnell DS. Adrenal androgens and the menopausal transition. Obstet Gynecol Clin North Am. 2011;38(3):467-475. doi: https://doi.org/10.1016/j.ogc.2011.06.001

23. Chen F, Knecht K, Birzin E, Fisher J, Wilkinson H, et al. Direct agonist/ antagonist functions of dehydroepiandrosterone. Endocrinology. 2005;146:4568–4576. doi: https://doi.org/10.1210/en.2005-0368

24. Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, et al. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric. 2015;18:590–607. doi: https://doi.org/10.3109/13697137.2014.992012

25. Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, et al. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015;22:1289–1295. doi: https://doi.org/10.1097/GME.0000000000000470

26. Chernova MO, Rozhivanov RV, Rozhivanova ER, Yesaulenko DI. The influence of correction of carbohydrate metabolism and body weight on endogenous testosterone production in men with type 2 diabetes mellitus, obesity and hypogonadism. Bulletin of Reproductive Health. 2024;3(2):33-40. (In Russ.) doi: https://doi.org/10.14341/brh12711

27. Huhtaniemi IT, Wu FCW. Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism. Best Pract Res Clin Endocrinol Metab. 2022;36(4):101622. doi: https://doi.org/10.1016/j.beem.2022.101622

28. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-135. doi: https://doi.org/10.1056/NEJMoa0911101

29. Han TS, Antonio L, Bartfai G, et al. Evidence-based definition of hypoprolactinemia in European men aged 40-86 years: the European male ageing study. Rev Endocr Metab Disord. 2024;25(6):1097-1107. doi: https://doi.org/10.1007/s11154-024-09890-0

30. Bhasin S, Lincoff AM, Basaria S, et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022;245:41-50. doi: https://doi.org/10.1016/j.ahj.2021.11.016

31. Clinical recommendation «Menopause and female climacteria», Moscow, 2025 (In Russ.)

32. Mikheev RK, Andreeva EN, Grigoryan OR, Sheremetyeva EV, Absatarova YuS, Uzhegova ZhA. Gynecological endocrinology and reproductive medicine from birth until the senescence: focus on the Reproductive Medicine Institute of the National Research Centre for Endocrinology. Problems of Endocrinology. 2025;71(1):4-9. (In Russ.) doi: https://doi.org/10.14341/probl13534

33. Adamyan LV, Andreeva EN et al. Сlinical recommendations of RSOG "Menopause and climacteric period among females. Version of year 2025". Bulletin of Reproductive Health. 2025;4(4):21-37. (In Russ.) doi: https://doi.org/10.14341/brh12782

34. ОEditorial T. Joint position of russian experts on the clinical significance of hyperandrogenism in early postmenopausal women // Obstetrics and Gynecology. - 2025. - N. 5. - P. 201-206. doi: https://doi.org/10.18565/aig.2025.118 (In Russ.)

35. https://www.whi.org/docs/2025-Annual.pdf // Women’s Health Initiative 2025 Annual Progress Report

36. Ilyushchenko AK, Machekhina LV, Strazhesko ID, Tkacheva ON. The role of IGF-1/ GH in the aging process and the development of age-related diseases. Obesity and metabolism. 2023;20(2):149-157. (In Russ.) doi: https://doi.org/10.14341/omet12934

37. van Bunderen CC, Deijen JB, Drent ML. Effect of low-normal and high-normal IGF-1 levels on memory and wellbeing during growth hormone replacement therapy: a randomized clinical trial in adult growth hormone deficiency. Health Qual Life Outcomes. 2018;16(1):135. doi: https://doi.org/10.1186/s12955-018-0963-2

38. Zhang WB, Ye K, Barzilai N, Milman S. The antagonistic pleiotropy of insulin-like growth factor 1. Aging Cell. 2021;20(9):e13443. doi: https://doi.org/10.1111/acel.13443

39. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1-6. doi: https://doi.org/10.1056/NEJM199007053230101

40. Harlow SD, Gass M, Hall JE, et al.; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387–395

41. Prior JC 1998 Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 19:397–428

42. Santoro N, Lasley B, McConnell D, Allsworth J, Crawford S, et al. Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: The Study of Women's Health across the Nation (SWAN) Daily Hormone Study. J Clin Endocrinol Metab. 2004;89(6):2622-31. doi: https://doi.org/10.1210/jc.2003-031578

43. Verrilli L, Berga SL. What Every Gynecologist Should Know About Perimenopause. Clin Obstet Gynecol. 2020;63(4):720-734. doi: https://doi.org/10.1097/GRF.0000000000000578

44. Davis SR, Taylor S, Hemachandra C, Magraith K, Ebeling PR, Jane F, Islam RM. The 2023 Practitioner's Toolkit for Managing Menopause. Climacteric. 2023;26(6):517-536. doi: https://doi.org/10.1080/13697137.2023.2258783

45. Frederiksen H, Johannsen TH, Andersen SE, Petersen JH, Busch AS, et al. Sex- and age-specific reference intervals of 16 steroid metabolites quantified simultaneously by LC-MS/MS in sera from 2458 healthy subjects aged 0 to 77 years. Clin Chim Acta. 2024;562:119852. doi: https://doi.org/10.1016/j.cca.2024.119852

46. Samaras N, Papadopoulou M, Samaras D, Ongaro F. Off-label use of hormones as an antiaging strategy: a review. CIA. 2014;1175. doi: https://doi.org/10.2147/cia.s48918

47. Lois K, Kassi E, Prokopiou M, Chrousos G.P. Adrenal Androgens and Aging. [Updated 2014 Jun 18]. In: De Groot LJ, Chrousos G, Dungan K, et al. (editors). Endotext [электронныйресурс]. South Dartmouth (MA): MDText.com, Inc.; 2000. Доступно по: http://www.ncbi.nlm.nih.gov/books/NBK279006/

48. Sultana F, Davis SR, Islam RM. Effect of dehydroepiandrosterone therapy on cognitive performance among postmenopausal women: a systematic review of randomized clinical trial data. Menopause. 2023;30(11):1167-1173. doi: https://doi.org/10.1097/GME.0000000000002251

49. Al-Sharefi A, Quinton R. Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations. Endocrinol Metab (Seoul). 2020;35(3):526-540. doi: https://doi.org/10.3803/EnM.2020.760

50. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018;103:1715-44

51. Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, et al. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust 2016;205:173-8

52. Dean JD, McMahon CG, Guay AT, Morgentaler A, Althof SE, Becher EF, et al. The International Society for Sexual Medicine’s process of care for the assessment and management of testosterone deficiency in adult men. J Sex Med 2015;12:1660-86

53. Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossei-Gerning N, et al. British Society for Sexual Medicine guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med 2017;14:1504-23

54. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. doi: https://doi.org/10.1016/j.juro.2018.03.115

55. Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123-135. doi: https://doi.org/10.1056/NEJMoa0911101

56. Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516. doi: https://doi.org/10.1210/jc.2011-2513

57. Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017;102(3):1067-1075. doi: https://doi.org/https://doi.org/10.1210/jc.2016-3580

58. Mazzola CR, Katz DJ, Loghmanieh N et al: Predicting biochemical response to clomiphene citrate in men with hypogonadism. J Sex Med 2014; 11: 2302